EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying novel inhibitors against drug-resistant mutant CYP-51 Candida albicans: A computational study to combat fungal infections

Saadia Jabeen, Muhammad Umer Khan, Hasan Ejaz, Shakeel Waqar, Aisha Farhana, Muharib Alruwaili, Yasir Alruwaili, Abualgasim Elgaili Abdalla, Sahar Mudassar, Qurban Ali iD

PLOS ONE · 04.03.2025 · 20 (3) · e0318539

DOI: 10.1371/journal.pone.0318539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 04.03.2025. Verfasst von Saadia Jabeen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan. Hauptthemen laut MEDLINE: Candida albicans, Antifungal Agents, Drug Resistance, Fungal, Fungal Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Graduate Studies and Scientific Research at Jouf University through the Fast-Track Research Funding Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida albicans (C. albicans) is an opportunistic pathogen in immunocompromised individuals and a normal inhabitant of the oral cavity, throat, gastrointestinal tract, and genitourinary system among health populations. Our study focused on identifying new inhibitors capable of binding to the mutant cytochrome P450 family 51 (CYP-51) protein and intended to be effective against resistant C. albicans infections. The pharmacophore ligand-based model was used for the virtual screening of compound libraries. Molecular docking was performed on Maestro, Schrodinger. ADMET analysis was performed to check drug-likeness properties. Density function theory (DFT) calculations, molecular dynamic (MD) simulation, and free binding energy (MMPBSA) were also calculated. For docking, six compounds were selected from 11,022 hits from PubChem libraries, which showed the best interaction with mutant CYP-51 and were identified by pharmacophore mapping performed with the Pharma IT tool. Each of the six compounds was docked into the active site of the mutant CYP-51 protein. Overall, CP-3 exhibited significant binding affinity (−10.70 kcal/mol) as well as, showed good ADMET characteristics such as drug-likeness, absorption, distribution, metabolism, excretion, and toxicity. The lead compound, CP-3, was further used for MD simulation to observe the dynamic behavior of the complex in the active site of the mutant CYP-51 protein. Computational studies indicated that CP-3 could be a useful antagonist for the mutant protein, CYP-51. This study used computational approaches to identify potential inhibitors of C. albicans by targeting CYP-51 for antifungal drug development. Further invitro and in vivo studies are needed to evaluate its pharmacokinetic properties and efficacy as a novel antifungal drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candida albicansAntifungal AgentsDrug Resistance, FungalFungal ProteinsCytochrome P-450 Enzyme SystemCytochrome P450 Family 51Molecular Docking SimulationMolecular Dynamics SimulationMutationHumans

Substanzen

Antifungal AgentsFungal Proteinscytochrome P-450 CYP51, Candida albicansCytochrome P-450 Enzyme SystemCytochrome P450 Family 51

Autor:innen und Institutionen

  • Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
  • Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka, Saudi Arabia.
  • Department of Pathology and Laboratory Medicine, Auckland City Hospital, Auckland, New Zealand.
  • Department of Pathology, Rashid Latif Medical College, Lahore, Pakistan.
  • Department of Plant Breeding and Genetics, Faculty of Agricultural Sciences, University of the Punjab, Lahore, Pakistan.

ORCID-Profile: Qurban Ali

Förderung

  • Deanship of Graduate Studies and Scientific Research at Jouf University through the Fast-Track Research Funding Program

Zitieren

APA

Jabeen, S., Khan, M. U., Ejaz, H., Waqar, S., Farhana, A., Alruwaili, M., Alruwaili, Y., Abdalla, A. E., Mudassar, S., & Ali, Q. (2025). Identifying novel inhibitors against drug-resistant mutant CYP-51 Candida albicans: A computational study to combat fungal infections. PLOS ONE, 20(3), e0318539. https://doi.org/10.1371/journal.pone.0318539

Vancouver

Jabeen S, Khan MU, Ejaz H, Waqar S, Farhana A, Alruwaili M, et al. Identifying novel inhibitors against drug-resistant mutant CYP-51 Candida albicans: A computational study to combat fungal infections. PLOS ONE. 2025;20(3):e0318539. doi:10.1371/journal.pone.0318539

BibTeX
@article{Jabeen2025,
  author = {Jabeen, Saadia and Khan, Muhammad Umer and Ejaz, Hasan and Waqar, Shakeel and Farhana, Aisha and Alruwaili, Muharib and Alruwaili, Yasir and Abdalla, Abualgasim Elgaili and Mudassar, Sahar and Ali, Qurban},
  title = {Identifying novel inhibitors against drug-resistant mutant CYP-51 Candida albicans: A computational study to combat fungal infections},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {e0318539},
  doi = {10.1371/journal.pone.0318539}
}
Kostenlos starten →